Register entry
- Registered sites
- 0
- Active NDC listings
- 1
- Live patents
- 6
- Exclusivities
- 1
- Countries
- 0
Exclusivity
Patents and exclusivities
6| Patent | Product | Covers | Expiry |
|---|---|---|---|
| 11592396 | LUMISIGHTpegulicianine acetate | substance | Sept 2030 |
| 9155471 | LUMISIGHTpegulicianine acetate | use | Oct 2031 |
| 10285759 | LUMISIGHTpegulicianine acetate | use | Dec 2031 |
| 9032965 | LUMISIGHTpegulicianine acetate | use | Dec 2031 |
| 9532835 | LUMISIGHTpegulicianine acetate | use | Dec 2031 |
| 9763577 | LUMISIGHTpegulicianine acetate | substance, product | Sept 2034 |
| Product | Exclusivity | Until |
|---|---|---|
| LUMISIGHTPEGULICIANINE ACETATE | NCE New chemical entity | Apr 2029 |
Catalogue
Marketed products
1| Brand | Generic name | Form / route | NDC |
|---|---|---|---|
| LUMISIGHT | Pegulicianine | injection, powder, lyophilized, for solution, intravenous | 82292-040NDA |
Enquiry
Common questions
- Is Lumicell, Inc. FDA approved?
- Lumicell, Inc. holds no registered establishment of its own; 1 drug product is listed under its name in the National Drug Code Directory, made at sites registered to other firms.
- What drugs does Lumicell, Inc. make?
- 1 product is listed under Lumicell, Inc. in the openFDA NDC Directory, most often as injection, powder, lyophilized, for solution. The full breakdown by dosage form and route is above. A listing count is not a sales figure.
Compiled from FDA establishment registrations, the openFDA NDC Directory, the Orange Book and the FDA drug shortage database. Not claimed by the company. Sources and methodology.